BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor
May 31, 2017 at 04:04 AM EDT
* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.
